Thiazolidinedione use and the risk of fractures.
Toulis
Konstantinos A
KA
Goulis
Dimitrios G
DG
Anastasilakis
Athanasios D
AD
D015519:Bone Density / Q000187:drug effects; D016022:Case-Control Studies; D016001:Confidence Intervals; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000139:chemically induced* / Q000453:epidemiology*; D006115:Greece; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D016017:Odds Ratio; D000077205:Pioglitazone; D012016:Reference Values; D018570:Risk Assessment; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C089946:2,4-thiazolidinedione; D000077205:Pioglitazone